Migraine and Periods: Study Looks at the Mechanisms

What Is Menstrual Migraine?

Menstrual migraine is a migraine attack that occurs within a specific window around menstrual bleeding. Clinical criteria generally define that window as two days before the first day of bleeding through the first three days of the period. The pattern should appear in at least two out of three menstrual cycles to be considered reliably menstrual.

Doctors distinguish between two patterns:

• Pure menstrual migraine: Attacks occur during the menstrual window and not at other times of the cycle.
• Menstrually related migraine: Attacks occur around menstruation but also happen at other times during the month.

The second pattern is more common. Menstrual attacks are also frequently longer, more disabling, and more likely to return after treatment than attacks occurring outside the menstrual window. In other words, the calendar may predict the migraine, but that does not make the experience any less disruptive.

Symptoms can extend far beyond head pain

A menstrual migraine may cause throbbing or pulsing pain, often on one side of the head. Movement can intensify it. Nausea, vomiting, dizziness, fatigue, neck discomfort, brain fog, and sensitivity to light, sound, or smells may accompany the pain.

Some people experience aura, such as flashing lights, blind spots, tingling, or temporary difficulty speaking. However, menstrual migraine is especially associated with migraine without aura. Because new neurological symptoms can also signal an emergency, a first or dramatically different aura should be medically evaluated.

The Study Connecting Menstruation, Estrogen, and CGRP

The 2023 cross-sectional, matched-cohort study involved 180 cisgender women. Researchers divided them into three hormonal groups: participants with regular menstrual cycles, participants using combined hormonal contraception, and postmenopausal participants. Within each group, women with episodic migraine were compared with age-matched controls who did not have migraine.

Researchers collected blood and tear-fluid samples to measure CGRP. Participants with natural menstrual cycles were assessed during menstruation, when estrogen is low, and around ovulation, when estrogen is substantially higher. Participants using contraceptives were assessed during the hormone-free interval and while taking active hormones. Postmenopausal participants were tested once.

The central finding

Among participants with regular cycles, those with migraine had significantly higher CGRP concentrations during menstruation than controls. Average blood levels were approximately 5.95 picograms per milliliter in the migraine group and 4.61 picograms per milliliter among controls. The difference was even more noticeable in tear fluid: approximately 1.20 nanograms per milliliter compared with 0.40 nanograms per milliliter.

That contrast was not observed around ovulation. Researchers also did not find the same menstrual-pattern difference among participants using hormonal contraceptives or those who were postmenopausal.

The results suggest that naturally fluctuating reproductive hormones may influence CGRP release in people biologically susceptible to migraine. Think of estrogen and CGRP as two members of a complicated group chat: the study confirms they appear to be communicating, although researchers have not yet recovered the entire message history.

How Could Falling Estrogen Trigger Migraine?

Estrogen rises and falls throughout the menstrual cycle. After increasing before ovulation and again during the luteal phase, its concentration drops sharply when pregnancy does not occur. Menstrual bleeding follows. For some people with migraine, this rapid change may lower the brain’s threshold for an attack.

The traditional estrogen-withdrawal hypothesis dates back decades. It proposes that the change in estrogen matters more than simply having a low estrogen level. Observations during pregnancy and perimenopause support that general idea: migraine often improves when estrogen remains relatively stable during pregnancy, while unpredictable fluctuations during perimenopause can make attacks more frequent.

However, estrogen does not operate a large red button labeled “START MIGRAINE.” Its influence is distributed across several interconnected systems.

Estrogen affects pain-processing pathways

Estrogen receptors are present in the trigeminal system, a network of nerves and brain structures central to migraine. Hormonal changes may alter how easily these neurons become excited, how the brain processes sensory information, and how strongly a person responds to pain.

Estrogen also interacts with serotonin, glutamate, nitric oxide, and other chemical messengers. A sudden decline may weaken mechanisms that normally control pain while making excitatory signaling more influential. The result is not guaranteed migraine, but a nervous system standing closer to the edge.

CGRP helps transmit and amplify migraine pain

CGRP is a neuropeptide released by sensory nerves, including fibers in the trigeminovascular system. It supports communication between nerve cells, promotes vasodilation, and contributes to inflammation-like signaling and pain sensitization around the tissues covering the brain.

Administering CGRP experimentally can provoke attacks in people with migraine, while medications that block CGRP or its receptor can treat or prevent attacks. This makes CGRP more than an interesting laboratory measurement; it is a biologically and clinically meaningful part of migraine.

The study supports a model in which falling estrogen is associated with greater CGRP release during menstruation. Higher CGRP activity could then intensify trigeminal signaling and make light, sound, movement, and ordinary sensory input feel as welcome as a marching band in a library.

Prostaglandins may add another layer

During menstruation, the uterine lining releases prostaglandins, chemicals that help the uterus contract. Higher prostaglandin activity is associated with cramps, inflammation, nausea, and pain. Although prostaglandins are not the primary focus of the CGRP study, they may help explain why menstrual migraine can overlap with abdominal pain and feel especially severe.

Hormonal withdrawal, CGRP signaling, prostaglandins, sleep disruption, stress, dehydration, missed meals, and genetic susceptibility may all contribute. Migraine is usually a threshold disorder: several factors accumulate until the nervous system crosses the line into an attack.

What the Study Does Not Prove

The findings are promising, but “associated with” is not the same as “caused by.” The researchers measured participants at selected points rather than continuously following every biochemical change through multiple cycles. A cross-sectional design can reveal differences between groups, but it cannot establish the exact sequence of events.

The study was also relatively small, and CGRP is difficult to measure consistently because its concentration can vary by sample type, collection method, processing, and timing. Tear-fluid analysis remains an experimental research tool rather than a routine test for diagnosing menstrual migraine.

Participants using hormonal contraception and postmenopausal participants did not show the same CGRP pattern, but that does not mean CGRP plays no role in their attacks. Their migraine biology may involve localized CGRP release that is not reflected in peripheral samples, different timing, or additional pathways that the study could not detect.

Finally, these results do not show that CGRP-blocking drugs work better specifically for menstrual attacks than other appropriately selected treatments. That clinically useful question requires dedicated randomized trials.

What the Research Could Mean for Treatment

The study strengthens the rationale for matching treatment to predictable hormonal patterns. A clinician may recommend acute therapy, short-term prevention around menstruation, continuous prevention, hormonal management, or a combination based on attack frequency and medical history.

Acute treatment at the start of an attack

Acute options may include nonsteroidal anti-inflammatory drugs, triptans, gepants, anti-nausea medication, or other prescription therapies. Treatment often works best when taken early, before pain and central sensitization become firmly established.

NSAIDs are not appropriate for everyone, particularly people with certain kidney, gastrointestinal, bleeding, or cardiovascular conditions. Triptans also require medical review for people with specific vascular diseases. A personalized plan is safer than borrowing a friend’s medication or improvising from the mysterious back corner of the medicine cabinet.

Short-term prevention for predictable periods

When cycles and attacks are predictable, clinicians sometimes use “mini-prevention” or bridge therapy. This involves taking medication for several days beginning shortly before the expected migraine window. Depending on the individual, a doctor may consider a long-acting triptan, an NSAID, or magnesium.

Timing matters. Starting too late may reduce the preventive benefit, while unnecessary or excessive acute-medication use can contribute to medication-overuse headache. A headache and period diary makes the treatment window easier to identify.

Continuous migraine prevention

People who experience attacks throughout the month may need an ongoing preventive treatment rather than a period-only strategy. Options can include certain blood-pressure medicines, antiseizure medicines, antidepressants, onabotulinumtoxinA for eligible chronic migraine, neuromodulation devices, gepants, or monoclonal antibodies targeting CGRP or its receptor.

The best choice depends on headache frequency, pregnancy plans, other health conditions, side-effect preferences, insurance coverage, and previous treatment responses. Biology may be complicated, but the treatment plan should not feel like it was designed by an escape-room enthusiast.

Hormonal strategies require individualized care

Continuous or extended-cycle hormonal contraception can reduce estrogen-withdrawal episodes in some people. In others, hormonal contraception has no effect or makes migraine worse. Estrogen-containing contraception is generally avoided in people with migraine with aura because of concern about ischemic stroke risk, especially when additional risk factors such as smoking or hypertension are present.

Hormonal treatments should therefore be discussed with a qualified clinician. Migraine type, age, cardiovascular risk, reproductive goals, and contraceptive needs all belong in that conversation.

How to Recognize Your Own Pattern

Track menstrual bleeding and headache symptoms for at least three cycles. Record the first day of bleeding, headache start and end times, pain severity, aura, nausea, sensory sensitivity, sleep, meals, medications, and how well each treatment worked.

A diary can answer practical questions:

• Do attacks repeatedly begin one or two days before bleeding?
• Are menstrual attacks longer or harder to treat?
• Does pain return after medication initially works?
• Are attacks also occurring around ovulation or elsewhere in the month?
• Did the pattern change after starting contraception or entering perimenopause?

Regular sleep, adequate hydration, consistent meals, manageable caffeine intake, gentle exercise, and stress management may help keep the migraine threshold from dropping further. These habits support treatment, but they do not mean migraine is caused by poor self-discipline. Nobody has ever defeated a neurological disorder through moral superiority and a prettier water bottle.

When a Headache Needs Prompt Medical Attention

Seek urgent care for a sudden, explosive headache; the worst headache of your life; new weakness, numbness, confusion, fainting, seizure, trouble speaking, or persistent vision loss; headache after a significant injury; or headache accompanied by fever and a stiff neck.

Arrange a routine medical evaluation when attacks are becoming more frequent, symptoms have changed, over-the-counter medicine is used repeatedly, treatment no longer works, or migraine regularly interferes with work, school, caregiving, sleep, or relationships. Predictable suffering is still suffering, and losing several days every month deserves proper care.

Experiences of Living With Migraine and Periods

The following composite experiences reflect commonly reported patterns. They are illustrative rather than the medical histories of identifiable individuals.

The migraine that arrives before the calendar reminder

Imagine Maya, whose first warning is not bleeding but a familiar pressure behind one eye. By lunchtime, office lights look aggressively bright, ordinary conversations sound amplified, and the smell of reheated food seems to have acquired legal permission to attack her personally. Her period usually begins the following morning.

For years, Maya treated each episode as an isolated bad headache. She took medication only after the pain became severe, then wondered why relief was slow and incomplete. Tracking three cycles changed the picture. Nearly every major attack began within 36 hours of menstruation, and the pain often returned the next day.

Her diary gave her clinician enough information to discuss a menstrual migraine plan. The most meaningful change was not a miraculous cure. It was predictability: keeping approved medication available, eating regularly during the vulnerable window, protecting sleep, and treating early. The calendar stopped feeling like an ambush schedule.

When cramps and migraine compete for first place

Jordan’s attacks begin on the first day of bleeding, alongside severe cramps and nausea. At first, it is difficult to tell which symptom started the cascade. Skipping breakfast because of nausea leads to dehydration, and lying awake with cramps reduces sleep. By afternoon, head pain has joined the party without bringing snacks.

Jordan’s experience illustrates why menstrual migraine is rarely about one chemical acting alone. Hormone withdrawal may lower the neurological threshold, while prostaglandins, disrupted meals, pain, and poor sleep push the system closer to an attack. Treating only the headache leaves several contributing problems untouched.

With medical guidance, Jordan develops a coordinated plan for cramps, nausea, hydration, and migraine. The plan includes clear limits on medication use and instructions about when to call the clinic. Having those details written down matters because remembering complicated directions during brain fog is roughly as easy as assembling furniture during a fire drill.

A changing pattern during perimenopause

Elena once had reliably timed attacks two days before every period. In her mid-40s, her cycles become irregular, and migraine follows suit. Some months bring no attack; others bring several. Her old short-term prevention schedule becomes difficult to time because the menstrual window keeps moving.

Elena initially blames herself. She reviews every meal, stressful conversation, and missed workout as if conducting a criminal investigation. Her clinician explains that perimenopause can produce wider and less predictable hormone fluctuations. The changing pattern is biological, not evidence that she has failed at migraine management.

Because attacks now occur throughout the month, Elena discusses continuous prevention instead of relying only on period-based treatment. She also reviews whether hormonal therapy is appropriate given her migraine type and overall health. The process takes patience and several follow-ups, but the goal becomes realistic control rather than perfect hormonal obedience.

The shared lesson

These experiences differ, yet they reveal the same practical truth: recognizing a menstrual pattern can turn vague suffering into usable clinical information. A diary will not stop estrogen from fluctuating or CGRP from doing biochemical mischief, but it can help patients and clinicians choose better timing, safer treatments, and more realistic expectations.

Conclusion

The study linking menstruation with higher CGRP concentrations gives researchers a plausible biological bridge between estrogen withdrawal and migraine pain. It supports the idea that a rapid hormonal change may influence the trigeminovascular system and increase CGRP signaling in susceptible people.

That bridge is not yet a complete map. Larger longitudinal studies must determine exactly when CGRP changes, whether those changes predict attacks, and which treatments work best for menstrual migraine specifically. For now, careful tracking and individualized medical care remain the most useful tools. A period-related migraine is not “just hormones,” and it is certainly not something a person must quietly surrender several days to every month.